The End the Vaccine Carveout Act would expose vaccine makers to lawsuits that once drove companies out of the industry.

But just a week lat­er, on Feb. 18, the FDA back­tracked on its decision, saying that it will indeed review the vaccine, potentially in time for its approval for the ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...

EMA backs Moderna’s dual COVID-19 and flu vaccine, mCombriax, paving the way for EU approval ahead of the 2026–2027 season.

Individuals share their journeys battling cancer and their experiences with groundbreaking immunotherapy treatments.

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for ...

The U.S. FDA’s expectations that its new default position of basing marketing authorization of novel drugs on one adequate, well-controlled trial may be overstated. In explaining the policy in a ...

Empower Pharmacy could be banned from doing business in California after the state's pharmacy board moved to revoke Empower’s ...

Despite trailing in case counts, RSV sent more than 800 people to the hospital — outpacing the flu’s 314 hospitalizations and ...

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...